SEASONED TEAM WITH A PROVEN TRACK RECORD

Novel Pharma has an experienced team consisting of researchers with knowledge, experience, and know-how in the overall value chain of development of rare disease therapeutics, ranging from finding candidate materials to preclinical, clinical trials and commercialization.

The researchers of Novel Pharma have a distinguished record of developing Hunterase IV-ERT and ICV-ERT for Hunter syndrome.

Meet Our Leadership

Novel Pharma’s team consists of research, clinical and business experts in rare diseases, especially in rare pediatric lysosomal storage diseases.

  • Dong-Kyu Jin, M.D., Ph.D.

    Chief Scientific Officer

    President of the Association for Research of MPS and Rare Diseases
    President of the Korea Society of Inherited Metabolic Disease
    Head of Pediatrics & Adolescent Department in Samsung Medical Center
    Director of Clinical Trial Center in Samsung Medical Center
    Professor, Sungkyunkwan University School of Medicine
    Bachelor of Medicine, MA, Ph.D, Seoul National University College of Medicine

  • Chan-Ho Park

    Chief Executive Officer

    22 years of investing and M&A advisory experience
    CEO, CP Partners (PE)
    Mount Kellet Capital (Hong Kong, Managing Director)
    Warburg Pincus Asia (Hong Kong, Principal)
    Goldman Sachs (Investment Banking Division)
    BA, Seoul National University College of Business Administration / AICPA

  • Ah-Ra Ko, Ph.D.

    Head of Translational Research

    Researcher, Seoul National University Hospital Biomedical Research Institute
    Senior Researcher, Samsung Medical Center Research Institute for Future Medicine
    Research Professor, Sungkyunkwan University College of Medicine
    Ph.D in Immunology, Seoul National University College of Medicine

  • Jin-Sup Kim, M.D., Ph.D.

    Head of Clinical Development

    10 years of clinical experience in rare/endocrine diseases
    Ph.D, Sungkyunkwan University College of Medicine
    MD, Specialty for Pediatric Endocrinology
    MD, Medical Geneticist
    Member of Pediatric Endocrinology Legislation/Medical Insurance Committee, KSPE
    Clinical Assistant Professor, Hanyang University Medical Center

  • Jong-Sun Park

    Chief Financial Officer

    17 years of investing and M&A advisory experience
    Executive Director, CP Partners (PE)
    Deputy Department Head of Korea Team, ORIX Corporation (Tokyo, Japan) Global Business Headquarters
    Manager of International Finance, Daiwa Securities SMBC, Seoul Branch
    BA, Seoul National University College of Business Administration

  • Jung-Hun Kwak

    Head of Business Development

    10 years of experience in B/D for rare diseases
    GC Biopharma (Rare Disease Division, Brand Manager)
    Shinmin Trading Co., Ltd (China, Executive Director)
    Nankai University, Chinese Language & Culture

Scientific Advisory Board

Novel Pharma is working with top experts in the rare disease industry and academia.

  • Paul Harmatz, M.D., Ph.D.
    Professor of Pediatrics, UCSF
  • Torayuki Okuyama, M.D., Ph.D.
    Professor of Genomic medicine, Saitama Medical University
  • Julie B. Eisengart, Ph.D.
    Professor of Pediatrics, University of Minnesota
  • Jong-Hee Chae, M.D., Ph.D.
    Professor of Genomic medicine, Seoul National University Hospital